CardioRisk Calculator1.6.9 - App Store

CardioRisk Calculator(TM) simplifies cardiovascular risk stratification and is a Canadian dyslipidemia guidelines application.

CardioRisk Calculator(TM) provides:

-quick calculations on % LDL-C reductions
-concise drug dosage information
-clear snapshot of a patient's CV risk
-options to bring lipid levels to target
-easy identification of familial hypercholesterolemia

This application has been developed with the ultimate goal of educating physicians on the most recent Canadian dyslipidemia guidelines and guidelines for the diagnosis of familial hypercholesterolemia.

Programming support for the CardioRisk Calculator(TM) was provided through unrestricted grants to support the CardioRisk Clinic from the following (in alphabetical order):

- Amgen Canada
- Bayer Inc
- Boehringer Ingelheim (Canada) Ltd
- FH Canada
- HLS Therapeutics
- Janssen Inc
- Novo Nordisk Canada
- Sanofi Canada

Version History - UPDATED FEATURE: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults - expanded paragraph regarding statin-indicated conditions 1.6.9 10/21/2023 NEW: Alternate LDL-C Calculator (for high Triglycerides) 1.6.8 06/27/2023 UPDATED FEATURE: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
NEW FEATURE: Simple Framingham Risk Score Calculator
NEW FEATURE: Imputed LDL-C Calculator 1.6.6 03/12/2022 UPDATED FEATURE: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

NEW FEATURE: Simple Framingham Risk Score Calculator

NEW FEATURE: Imputed LDL-C Calculator 1.6.4 10/29/2021 UPDATED FEATURE: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

NEW FEATURE: Imputed LDL-C Calculator 1.6.1 10/01/2021 UPDATED FEATURE: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults 1.6.0 09/10/2021 UPDATED FEATURE: Additional unit(mg/g) for Albumin Creatinine Ratio 1.5.4 09/26/2020 UPDATED FEATURE: Diagnosis of apoB dyslipoproteinemias 1.5.3 08/12/2020 -Addition of Niacin/Fenofibrate Treatment field
-The updated Dyslipidemia Risk Calculator now accommodates patients already on lipid therapy in addition to patients new to drug treatment. 1.4.0 12/20/2018 -Addition of Bruits/AAA/Pulse Deficit fields
-Updated Dyslipidemia Risk Calculator
-Updated FH Calculator
-Misc. logic improvements 1.3.3 12/17/2017 -Updated Dyslipidemia Risk Calculator
-Updated FH Calculator
-Additional Reference Papers
-Fixed stability issue affecting iPad devices 1.3.1 11/09/2017 -Updated Dyslipidemia Risk Calculator
-Updated FH Calculator
-Additional Reference Papers 1.3.0 11/07/2017 Addition of Alirocumab 300 mg Q4W to options of PCSK9i drug class. 1.2.27 08/08/2017 Version 1.2.26: Improved French language support. Miscellaneous visual and performance improvements.

This version of CardioRisk Calculator™ is based on the most recent Canadian dyslipidemia guidelines, and guidelines for the diagnosis of familial hypercholesterolemia. 1.2.26 07/24/2017 Version 1.2.24: French language support, and miscellaneous visual improvements.

This version of CardioRisk Calculator™ refers to the most recent Canadian dyslipidemia guidelines, and guidelines for diagnosis of familial hypercholesterolemia. 1.2.24 05/02/2017 Version 1.2.21: Improvements for reliability and speed

This version of CardioRisk Calculator™ refers to the most recent Canadian dyslipidemia guidelines, and implements guidelines for diagnosis of familial hypercholesterolemia. Also, additional drug dosage information is provided. 1.2.21 02/23/2017 This version of CardioRisk Calculator™ refers to the most recent Canadian dyslipidemia guidelines, and implements guidelines for diagnosis of familial hypercholesterolemia. Also, additional drug dosage information is provided. 1.2.20 12/21/2016 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult - 2012 recommendations

-plus-

2014 Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease

-plus-

Statin myalgia clinical index score 1.1.41 01/16/2015 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult - 2012 recommendations

-plus-

2014 Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease 1.1.40 10/08/2014 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult - 2012 recommendations 1.1.28 03/26/2014 -Layout changes to the 2012 Canadian Guidelines module.

-Vascular Age ("Heart Age") is calculated in years rather than a range. 1.1.6 03/25/2013 Includes recommendations based upon the 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult 1.1.4 01/16/2013 Update to the Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance Guideline. (English and French) 1.0.17 02/13/2012 Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance 1.0.15 01/31/2012 1.0.8 12/22/2010